LONDON–(BUSINESS WIRE)–#Research–The unavailability of promising treatment options with fewer side effects and complications associated with uncontrolled high blood pressure are compelling governments and private organizations to increase their R&D investments. The rise in R&D will also lead to the development of therapeutics that can demonstrate better safety and efficacy than the available medications. The increased funds for R&D is one of the critical reasons that will drive the antihypertensive drugs market growth in the coming years. Furthermore, this industry research report also presents a competitive analysis of the market by type (systemic hypertension and pulmonary hypertension) and geography (Asia, Europe, North America, and ROW).
Competitive vendor landscape
The global antihypertensive drugs market is highly competitive with major vendors such as AstraZeneca, Johnson & Johnson Services, Inc., Merck & Co., Inc., Novartis AG, and Pfizer Inc. competing on the basis of price, quality, and product/service offerings.
“North America will account for the largest antihypertensive drugs market share throughout the forecast period. The high prevalence of hypertension and the rising awareness about the risk factors, prevention, diagnosis, and treatment of high blood pressure in the US is one of the major reasons for the high growth of the antihypertensive drugs market in this region,” says a senior analyst at Technavio
Top five antihypertensive drugs market vendors
AstraZeneca
AstraZeneca operates through the segment, biopharmaceuticals. The company’s key offerings include DUTOPROL, ZESTORETIC, and ZESTRIL.
Johnson & Johnson Services, Inc.
Johnson & Johnson Services, Inc. runs its operations through three segments: consumer, pharmaceutical, and medical devices. The company’s key offerings include: OPSUMIT, TRACLEER, UPTRAVI, VELETRI, and VENTAVIS.
Merck & Co., Inc.
Merck & Co., Inc. runs its operations through two segments: pharmaceutical and other. The company’s key offerings include COZAAR, HYZAAR, and PRINIVIL.
Novartis AG
Novartis AG runs its operations through three segments: innovative medicines, sandoz, and alcon. The company’s key offerings include DIOVAN, DIOVAN HCT, ENTRESTO, EXFORGE HCT, and LOTREL.
Pfizer Inc.
Pfizer Inc. runs its operations through two segments: innovative health and essential health. The company’s key offerings include ACCURETIC, NORVASC, and REVATIO.
Looking for more information on this market? Request a free sample report
Technavio’s sample reports are free of charge and contain multiple sections of the report including the market size and forecast, drivers, challenges, trends, and more.
Browse Related Reports:
- Global Pruritus Drugs Market 2019-2023 – The market research study identifies Allergan Plc, Astellas Pharma Inc., GlaxoSmithKline Plc, Pfizer Inc., and Sanofi, as the leading players in the global pruritus drugs market.
- Global Uveitis Drugs Market 2019-2023 – The market research study identifies AbbVie Inc., Allergan Plc, Johnson & Johnson Services Inc., Novartis AG, and Pfizer Inc., as the leading players in the global uveitis drugs market.
About Technavio
Technavio is a leading global technology research and advisory company. Their research and analysis focuses on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions.
With over 500 specialized analysts, Technavio’s report library consists of more than 10,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio’s comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.
If you are interested in more information, please contact our media team at media@technavio.com.
Contacts
Contacts
Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
technavio.com
media@technavio.com.